Arca
Skip to content
Tools
Tools

TBXA2R: Thromboxane A2 receptor

Receptor for thromboxane A2 (TXA2), a potent stimulator of platelet aggregation.

  • Drugs that act on it: 5
  • Approved: 3
  • In phases 1 to 3: 2
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on TBXA2R, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 5

Approved3

  • Picotamide
  • Ramatroban
  • Seratrodast

Phase 31

  • Terutroban

Phase 21

  • Terbogrel

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 5 act as: Thromboxane A2 receptor antagonist; the rest name their own mechanism.
    PicotamideApproved—Small moleculeInhibitorThromboxane A2 receptor inhibitor0
    RamatrobanApprovedKARE BiosciencesSmall moleculeAntagonist0
    SeratrodastApproved—Small moleculeAntagonist0
    TerutrobanPhase 3—Small moleculeAntagonist0
    TerbogrelPhase 2Boehringer Ingelheim PharmaceuticalsSmall moleculeAntagonist0

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Bleeding diathesis due to thromboxane synthesis deficiency0.60
    • Neurodegenerative disease0.51
    • Airway obstruction0.37
    • Recurrent thrombophlebitis0.37
    • Abnormal platelet aggregation0.30
    • Thrombotic disease0.26
    • Allergic asthma0.26
    • Autoimmune disorder of central nervous system0.20
    • Hereditary disease0.19
    • Atopic asthma0.19
    • Blood platelet disease0.18

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2069, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P21731, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.